Caio Falk Giannotti

Caio Falk Giannotti

Auto-generated profile, based on publicly available information

Caio Falk Giannotti

Universidade Federal de São Paulo, Brazil

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2026 in Acta Ortopedica Brasileira
Verified
Journal Article
Open access
CGCaio Falk Giannotti
Caio Falk Giannotti
NONathalia Sundin Palmeira de Oliveira
Nathalia Sundin Palmeira de Oliveira
JGJairo Greco Garcia
Jairo Greco Garcia
MPMarcelo de Toledo Petrilli
Marcelo de Toledo Petrilli
DVDan Carai Maia Viola
Dan Carai Maia Viola
RFReynaldo Jesus Garcia Filho
Reynaldo Jesus Garcia Filho
Objective: The Aneurysmal Bone Cyst (ABC) is a benign yet aggressive bone tumor. This study aimed to evaluate sex, age, tumor location, tumor size, type of treatment (surgical, infiltration, embolization), and recurrence. Methods: Descriptive and quantitative statistical analyses were applied. The prevalence ratio and 95% confidence interval were calculated for the association between recurrence and sex, age, tumor size, Capanna's classification, and treatment type. Results: Twenty-three cases of ABCs were included, eleven (47.8%) females and twelve (52.2%) males. The mean age of treated patients was 11.2±1.8 years. Most cysts were located in the lower limbs (56.5%). The mean follow-up time was 42.8±14.01 months. The mean cyst diameter at the beginning of treatment was 5.58± 1.04 cm; of these, 17.4% were up to 3 cm, 43.5% from 3.1 to 6 cm, and 39.1% over 6 cm. Regarding initial treatment, 6 (26%) patients received infiltration, and in total 20 (86.9%) underwent surgery with bone grafting. The overall recurrence rate was 30.4%. No association was identified between recurrence and the variables studied (p ≥ 0.05). The epidemiological data obtained are consistent with pediatric cohorts reported in the literature. Conclusion: All evaluated methods are suitable for treating aneurysmal bone cysts. Level of Evidence IV; Case Series.

1 January 2025 in Acta Ortopedica Brasileira
Verified
Journal Article
Open access
PDF file
JDJulia Pozzetti Daou
Julia Pozzetti Daou
CGCaio Falk Giannotti
Caio Falk Giannotti
JGJairo Greco Garcia
Jairo Greco Garcia
MPMarcelo de Toledo Petrilli
Marcelo de Toledo Petrilli
DVDan Carai Maia Viola
Dan Carai Maia Viola
RFReynaldo Jesus Garcia Filho
Reynaldo Jesus Garcia Filho
Understanding the nature of musculoskeletal tumors is crucial for appropriate management and to secure a favorable prognosis. Orthopedists’ ability to identify these pathologies early and accurately is paramount. There is a requirement to raise awareness within the orthopedic community regarding the necessity of referrals to orthopedic oncology specialists, as delays in initiating proper treatment can compromise patient prognosis. Objective: The objective was to assess the capability of non-specialist orthopedists in identifying bone lesions suggestive of tumors and thus classify them by employing a questionnaire with radiographs and comparison with specialists. We aim to gain an in-depth understanding of their diagnostic competence and provide insights into teaching the subject in orthopedic residency programs. Methods: The sample consisted of 90 participants who answered the questionnaire: 18 orthopedic oncology specialists, 58 non-specialist orthopedists, and 14 orthopedic residents. Results: Specialists achieved an average accuracy of 12.50 ± 1.07, while non-specialists scored 10.00 ± 0.60 (p<0.001). Among non-specialists, there was no statistical significance when comparing whether they underwent specialization internship during residency nor the duration of the year of such training. The period since graduation also indicated no differences. Conclusion: This study highlights the importance of referring patients with suspected tumors to specialized orthopedists. Level of Evidence V; Expert Opinion.

1 January 2022 in Acta Ortopedica Brasileira
Verified
Journal Article
Open access
RDRene Dujardin
Rene Dujardin
DMDiego Praxedes DE Miras
Diego Praxedes DE Miras
CGCaio Falk Giannotti
Caio Falk Giannotti
RNRoberto Bezerra Nicolau
Roberto Bezerra Nicolau
EDEiffel Tsuyoshi Dobashi
Eiffel Tsuyoshi Dobashi
Objective: To evaluate medial joint space in affected and normal contralateral hips in patients with Legg-Calvé-Perthes disease (LCPD). Methods: To compare joint space, femoral head extrusion (FHE), medial space coefficient (MSC) of the hip, and femoral head width (FHW) in affected and normal hips, using 127 radiographs of patients with unilateral LCPD and considering age groups under and over six years old as well as their disease stage. Results: No statistically significant differences were observed regarding MSC between normal and affected hips regardless of disease staging. However, medial joint distance was significantly greater in affected hips than in normal hips. In the necrosis and fragmentation phase, distance from medial space in affected hips was significantly greater than in contralateral normal hips. Comparing only affected hips, MSC and FHW showed statistically significant differences and the group > 6 yo presented higher values. Among normal hips, the group < 6 yo presented a statistically significant difference considering the MSC and FHW. Conclusions: No statistically significant difference was found between the medial joint space of affected and normal hips, except for early stages of the disease (necrosis and fragmentation). The isolated use of radiographic study is insufficient in LCPD and the lack of complementation with other exams, such as magnetic resonance, can delay diagnosis of and onset of treatment for the disease. Level of Evidence III, Study of Non Consecutive Patients; without Consistently Applied Reference “Gold” Standard.

4 January 2026 in Revista Sociedade Científica
Verified
Journal Article
Open access
FFFrancisco Wellington Lopes Guimarães Filho
Francisco Wellington Lopes Guimarães Filho
MPMarcelo De Toledo Petrilli
Marcelo De Toledo Petrilli
JGJairo Greco Garcia
Jairo Greco Garcia
RFReynaldo Jesus-Garcia Filho
Reynaldo Jesus-Garcia Filho
CGCaio Falk Giannotti
Caio Falk Giannotti
RSRafael Muller dos Santos
Rafael Muller dos Santos
O tumor de células gigantes do osso é uma neoplasia osteolítica localmente agressiva na qual o denosumabe se tornou uma opção sistêmica importante, porém ainda há incerteza quanto à durabilidade do controle e à segurança em esquemas do mundo real. Este estudo teve como objetivo sintetizar a efetividade e a segurança do tratamento baseado em denosumabe em pacientes com TCGO com maturidade esquelética. Realizou-se busca nas bases PubMed, EMBASE, Scopus e Cochrane Library estudos clínicos em texto completo e em língua inglesa que avaliaram denosumabe em pacientes com maturidade esquelética e tumor de células gigantes do osso até janeiro de 2026. Os desfechos primários foram benefício clínico e eventos adversos, e os desfechos secundários foram resposta por imagem, recidiva local e falha do tratamento. Uma meta-análise de braço único com modelo de efeitos aleatórios foi realizada, com estabilização de variância e ponderação pelo inverso da variância. A heterogeneidade foi quantificada pelo I², e intervalos preditivos e análises leave-one-out foram utilizados para avaliar a robustez. As análises de subgrupo foram limitadas ao desenho do estudo. Foram analisados 22 estudos, incluindo 1.170 pacientes. A taxa combinada de benefício clínico foi de 79,94% (IC 95% 74,21–85,02; I² 85,8%), e a taxa combinada de resposta por imagem foi de 72,72% (IC 95% 59,46–84,04; I² 97,2%). A recidiva local ocorreu em 24,49% dos pacientes (IC 95% 14,30–36,54; I² 96,5%) e a falha do tratamento em 10,36% (IC 95% 6,74–14,69; I² 57,0%). A taxa combinada de eventos adversos foi de 31,16% (IC 95% 6,76–63,08; I² 98,5%). A análise de subgrupo por desenho do estudo não reduziu de forma consistente a heterogeneidade, os intervalos preditivos foram amplos para a maioria dos desfechos e a meta-regressão utilizando idade média e a proporção de pacientes do sexo feminino não identificou moderadores significativos das estimativas combinadas. Observou-se que o denosumabe esteve associado a benefício clínico significativo e resposta radiológica em pacientes com maturidade esquelética e TCGO, porém, a durabilidade do controle e as estimativas de segurança variaram amplamente entre os estudos, ressaltando a necessidade de desfechos padronizados e de evidência prospectiva comparativa.